Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus.
Lancet Rheumatol
; 5(3): e151-e165, 2023 Mar.
Article
en En
| MEDLINE
| ID: mdl-38251610
ABSTRACT
Systemic lupus erythematosus is a complex, systemic autoimmune disease characterised by immune dysregulation. Pathogenesis is multifactorial, contributing to clinical heterogeneity and posing challenges for diagnosis and treatment. Although strides in treatment options have been made in the past 15 years, with the US Food and Drug Administration approval of belimumab in 2011, there are still many patients who have inadequate responses to therapy. A better understanding of underlying disease mechanisms with a holistic and multiparametric approach is required to improve clinical assessment and treatment. This Review discusses the evolution of genomics, epigenomics, transcriptomics, and proteomics in the study of systemic lupus erythematosus and ways to amalgamate these silos of data with a systems-based approach while also discussing ways to strengthen the overall process. These mechanistic insights will facilitate the discovery of functionally relevant biomarkers to guide rational therapeutic selection to improve patient outcomes.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inteligencia Artificial
/
Lupus Eritematoso Sistémico
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Lancet Rheumatol
Año:
2023
Tipo del documento:
Article